Immunotherapy plus chemo shows promise for bile duct cancer in early trial

NCT ID NCT05967182

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) before and after surgery can improve outcomes for people with a type of bile duct cancer called intrahepatic cholangiocarcinoma. The trial will enroll 24 adults whose cancer is potentially removable. Researchers will monitor side effects and how well the treatment works compared to standard care alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (immunotherapy) plus gemcitabine and cisplatin (chemotherapy)
What this could lead to: If it works, this could point toward a more effective treatment approach for bile duct cancer, potentially improving survival after surgery.
What could go wrong: This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. Adding immunotherapy to chemo can also increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLANGIOCARCINOMA

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.